A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
NCT ID: NCT01611272
Last Updated: 2017-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3402 participants
OBSERVATIONAL
2013-04-30
2016-07-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brilinta Clinical Experience Investigation
NCT03212287
Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy
NCT05553717
Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data
NCT05086081
Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy
NCT02921126
Duration of Platelet Inhibition by Aspirin
NCT00671021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are taking ticagrelor and ASA daily(75-150mg), or Patients who are taking ticagrelor only(In the case that the patients have contraindication with ASA. Contraindication should be recorded in accordance with local PI on CRFs)
* Patients who have signed the Data release consent form prior to enrollment in this surveillance
Exclusion Criteria
* Patients with pathological hemorrhage at the time of administration
* Patients being administrated strong CYP3A4 inhibitors
19 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JooWon Lee
Role: STUDY_DIRECTOR
AstraZeneca Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Cheonan-si, Chungcheongnam-do, South Korea
Research Site
Chuncheon, Gangwon-do, South Korea
Research Site
Wŏnju, Gangwon-do, South Korea
Research Site
Ansan-si, Gyeonggi-do, South Korea
Research Site
Anyang-si, Gyeonggi-do, South Korea
Research Site
Bucheon-si, Gyeonggi-do, South Korea
Research Site
Goyang-si, Gyeonggi-do, South Korea
Research Site
Koyang-shi, Gyeonggi-do, South Korea
Research Site
Seongnam-si, Gyeonggi-do, South Korea
Research Site
Suwon, Gyeonggi-do, South Korea
Research Site
Andong, Gyeongsangbuk-do, South Korea
Research Site
Gumi, Gyeongsangbuk-do, South Korea
Research Site
Gimhae, Gyeongsangnam-do, South Korea
Research Site
Iksan-si, Jeollabuk-do, South Korea
Research Site
Jeonju, Jeollabuk-do, South Korea
Research Site
Suncheon-si, Jeollanam-do, South Korea
Research Site
Busan, , South Korea
Research Site
Daegu, , South Korea
Research Site
Daejeon, , South Korea
Research Site
Gwangju, , South Korea
Research Site
Incheon, , South Korea
Research Site
Seoul, , South Korea
Research Site
Ulsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5130L00019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.